A common practice for treating patients with gastrointestinal conditions has been revised by the American Gastroenterological Association, it announced Feb. 21. The group has expanded its ...

C. diff is a horrible disease that can cause significant morbidity. It can and often does recur and kills around 30,000 Americans every year. We have made progress in prevention and treatment, but ...

In the first comprehensive evidence-based guideline on the use of fecal microbiota-based therapies for gastrointestinal disease, the American Gastroenterological Association recommends fecal ...

Current guidelines recommend using either metronidazole or vancomycin to treat C. diff infections. “For many years the two antibiotics were considered to be equivalent in their ability to cure C. diff ...

Arlington, Va. — June 27, 2024 — A new study published today in the American Journal of Infection Control (AJIC) describes the outcome of a new approach to testing for Clostridioides difficile (C.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The American ...

Seres Therapeutics reported results from an interim phase 2 trial for its colon infection treatment weren’t found to be statistically significant. 1. The treatment, SER-109, is intended for multiply ...

There are inherent risks in biotech investing. A decade’s worth and often hundreds of millions of dollars in R&D, along with binary risks of failed clinical trials or regulatory approval. Above and ...

SALT LAKE CITY – Over the past two decades there has been a sharp rise in the number and severity of infections caused by the bacteria Clostridium difficile often shortened to C. diff now the most ...